The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
By John Mair-Jenkins, M. Saavedra-Campos, J. Baillie, P. Cleary, F. Khaw, W. Lim, Sophia Makki, K. Rooney, J. Nguyen-Van-Tam, C. Beck and 12 more. Journal of Infectious Diseases, 2014
964 citations recorded by the source corpus.
Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence. Methods. Healthcare databases and sources of grey literature were searched in July 2013. All records were screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of bias assessments were undertaken. Results. We identified 32 studies of SARS coronavirus infection and severe influenza. Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset. Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14–.45; I2 = 0%). Studies were commonly of low or very low quality, lacked control groups, and at moderate or high risk of bias. Sources of clinical and methodological heterogeneity were identified. Conclusions. Convalescent plasma may reduce mortality and appears safe. This therapy should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/d7790f7715eb7b0e7c983804165581a867a2927b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment (2020, background): “Several convalescent patients are donating plasma against COVID-19 based on the positive results of another coronavirus(Koenig, 2015; Mair-Jenkins et al., 2015).”
- Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence (2020, neutral): “When there are no sufficient vaccines and specific drugs, convalescent plasma therapy could be an effective way to alleviate the course of disease for severely infected patients [59] .”
- The cytokine storm and COVID‐19 (2020, result): “This approach has demonstrated promising results in the treatment of SARS and influenza.(80,81) However, a Cochrane systematic review revealed weak evidence on the effectiveness and safety of this therapy for patients with COVID‐19.”
- The epidemiology, diagnosis and treatment of COVID-19 (2020, methodology): “Convalescent plasma was administered early after symptom onset in the treatment of SARS, and the pooled odds of mortality following treatment was reduced compared with placebo or no therapy (odds ratio, 0.25) [78] .”